{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T20:55:30Z","timestamp":1794603330211,"version":"4.9.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":206,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ganymed Pharmaceuticals GmbH"},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Inc"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1093\/annonc\/mdz199","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T09:28:38Z","timestamp":1561454918000},"page":"1487-1495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":235,"title":["A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-9339","authenticated-orcid":false,"given":"O.","family":"T\u00fcreci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schulze-Bergkamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zvirbule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Koeberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Thuss-Patience","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Ettrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bassermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Wiechen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dhaene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Maurus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Krivoshik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arozullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1093\/annonc\/mdz199_bb0010","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.3748\/wjg.v20.i16.4483","article-title":"Characteristics of gastric cancer in Asia","volume":"20","author":"Rahman","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"10060","key":"10.1093\/annonc\/mdz199_bb0015","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","article-title":"Gastric cancer","volume":"388","author":"Van Cutsem","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdz199_bb0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdz199_bb0025","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"3","author":"Wagner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"9911","key":"10.1093\/annonc\/mdz199_bb0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1093\/annonc\/mdz199_bb0035","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/annonc\/mdq604","article-title":"A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma","volume":"22","author":"Chan","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz199_bb0040","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.35.15_suppl.4003","article-title":"KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer","volume":"35","author":"Fuchs","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10111","key":"10.1093\/annonc\/mdz199_bb0045","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"23","key":"10.1093\/annonc\/mdz199_bb0050","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdz199_bb0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","article-title":"A phase 1 dose-escalation study of IMAB362 (zolbetuximab) in patients with advanced gastric and gastro-esophageal junction cancer","volume":"100","author":"Sahin","year":"2018","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz199_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1093\/annonc\/mdz199_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdz199_bb0070","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, Version 3.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdz199_bb0075","doi-asserted-by":"crossref","first-page":"v122","DOI":"10.1093\/annonc\/mdx367.010","article-title":"Preclinical evaluation of the anti-CLDN18.2 antibody, IMAB362, in pancreatic carcinoma","volume":"28","author":"Heinz","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz199_bb0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11096-010-9462-1","article-title":"Induction-related cost of patients with acute myeloid leukaemia in France","volume":"33","author":"Nerich","year":"2011","journal-title":"Int J Clin Pharm"},{"key":"10.1093\/annonc\/mdz199_bb0085","first-page":"vi207","volume":"27","author":"Dudov","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz199_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/tgh.2016.03.03","article-title":"Ethnicity-related differences in tumor immunity: a new possible explanation for gastric cancer prognostic variability?","volume":"1","author":"Marrelli","year":"2016","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"5","key":"10.1093\/annonc\/mdz199_bb0095","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Cristescu","year":"2015","journal-title":"Nat Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419459905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419459905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz199\/28982117\/mdz199.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/9\/1487\/30092797\/mdz199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T14:08:33Z","timestamp":1668694113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419459905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0923753419459905"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz199","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdz199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}